OS Therapies (OSTX)
| Bid | 2 |
| Market Cap | 48.37M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -8.88M |
| EPS (ttm) | -0.88 |
| PE Ratio (ttm) | -2.31 |
| Forward PE | 38.12 |
| Analyst | Buy |
| Ask | 2.04 |
| Volume | 240,344 |
| Avg. Volume (20D) | 838,437 |
| Open | 1.89 |
| Previous Close | 1.93 |
| Day's Range | 1.87 - 2.05 |
| 52-Week Range | 1.12 - 7.00 |
| Beta | -6.19 |
About OSTX
OS Therapies Incorporated, a clinical stage biopharmaceutical company, focuses on the identification, development, and commercialization of treatments for osteosarcoma and other solid tumors in the United States. Its pipeline includes OST-HER2, an off-the-shelf immunotherapy for osteosarcoma patients; and OST-tunable drug conjugate (OST-tADC), an antibody-drug conjugate technology, with a plug-and-play platform that features tunable pH sensitive ...
Analyst Forecast
According to 4 analyst ratings, the average rating for OSTX stock is "Buy." The 12-month stock price forecast is $19.5, which is an increase of 860.59% from the latest price.
Stock Forecasts
3 weeks ago · https://www.marketscreener.com
Investing in the $532B Oncology Boom: Key Stocks Shaping the Future of Cancer TreatmentThe global oncology drug market, valued at over $200 billion today, is on pace to reach $532 billion by 2031-a growth story driven not just by rising demand but by genuine innovation. After years of i...
